Results 41 to 50 of about 18,455 (220)

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy

EJNMMI Research, 2022
Background Somatostatin receptor 68Ga PET imaging is standard for evaluation of a patient’s suitability for 177Lu peptide receptor radionuclide therapy of neuroendocrine tumours (NETs).
Anna Stenvall, Johan Gustafsson, Erik Larsson, Daniel Roth, Anna Sundlöv, Lena Jönsson, Cecilia Hindorf, Tomas Ohlsson, Katarina Sjögreen Gleisner   +8 more
doaj   +1 more source

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course

PLoS ONE, 2021
Background Mainly severe (CTCAE grade 3–4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common and could affect therapy ...
Daphne M. V. de Vries–Huizing, Michelle W. J. Versleijen, Michiel Sinaasappel, Iris Walraven, Martine M. Geluk–Jonker, Margot E. T. Tesselaar, Jeroen J. M. A. Hendrikx, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel   +8 more
doaj   +2 more sources

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors [PDF]

, 2010
Cholecystokinin (CCK) receptors are overexpressed in numerous human cancers, like medullary thyroid carcinomas, small cell lung cancers and stromal ovarian cancers.
Susan Roosenburg, Peter Laverman, Floris L. van Delft, Otto C. Boerman, L Aloj, L Aloj, MP Béhé, MP Béhé, MP Béhé, TM Behr, TM Behr, TM Behr, WAP Breeman, M Jong de, S Luca De, I Dijkgraaf, J Fichna, M Foucaud, AC Fröberg, S Good, M Gotthardt, R Haubner, MR Hellmich, A Imdahl, RB Innis, AC Ivy, AS Kopin, DJ Kwekkeboom, P Laverman, P Laverman, HR Maecke, SJ Mather, Y Matsumori, F Noble, F Noble, BA Nock, JA O’Donoghue, JC Reubi, J-C Reubi, J-C Reubi, H Sankaran, JP Smith, JR Upp Jr, JJ Vanderhaeghen, E Guggenberg von, SA Wank, SA Wank   +46 more
core   +1 more source

¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy [PDF]

Journal of Nuclear Medicine Technology, 2018
The peptide receptor radionuclide therapy (PRRT) 177Lu-DOTATATE binds to somatostatin receptors ([1][1]). A multidisciplinary team should be involved when treating patients with 177Lu-DOTATATE PRRT, including medical oncologists, nuclear medicine physicians and technologists, nurses ...
Amanda, Abbott, Heather, Jacene
openaire   +3 more sources

Molecular imaging of a glucagonoma with 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT imaging: A case report and review of the literature

Radiology Case Reports, 2020
A 35-year-old man presented with significant weight loss of 30 kg over the previous 6 months, with newly diagnosed diabetes. Routine laboratory tests were normal, except for markedly elevated blood glucose.
Ahmed Fathala, MD, Mohammed H. Al Qahtani, PhD, Moheieldin M. Abouzied, MD   +2 more
doaj   +1 more source

Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy

EJNMMI Physics, 2022
Purpose To evaluate if satisfactory post-therapeutic image-based dosimetry can be achieved for Lu-177-DOTATATE treatments using a reduced number of image acquisitions to improve patient comfort and reduce economical costs.
Oscar Ardenfors, Joachim N. Nilsson, Daniel Thor, Cecilia Hindorf   +3 more
doaj   +1 more source

The Integration of Positron Emission Tomography With Magnetic Resonance Imaging [PDF]

, 2008
A number of laboratories and companies are currently exploring the development of integrated imaging systems for magnetic resonance imaging (MRI) and positron emission tomography (PET).
Cherry, Simon R., Jacobs, Russell E., Louie, Angelique Y.   +2 more
core   +1 more source

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma [PDF]

Journal of Nuclear Medicine, 2020
Esthesioneuroblastoma is rare, with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in esthesioneuroblastoma from 2 referral centers.
Olfat Kamel, Hasan, Aravind S, Ravi Kumar, Grace, Kong, Kira, Oleinikov, Simona, Ben-Haim, Simona, Grozinsky-Glasberg, Rodney J, Hicks   +6 more
openaire   +2 more sources

[111In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: An overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy [PDF]

, 2014
Aims: With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic neuroendocrine tumor (GEPNET) liver metastases we explored the effect of intra-arterial (IA) administration of [111In-DTPA]octreotide ...
Breeman, W.A.P. (Woulter), Eijck, C.H.J. (Casper) van, Hagen, T.L.M. (Timo) ten, Jong, M. (Marcel) de, Kam, B.L. (Boen), Konijnenberg, M. (Mark), Koning, G.A. (Gerben), Krenning, E.P. (Eric), Pool, S.E. (Stefan)   +8 more
core   +2 more sources